HARNESSING DNAto personalize
cancer treatment
The future of healthcare is in accessing & using greater information about the individual. DNAmito is expanding their DNA testing platform enabling early chronic disease prediction, transforming its management; leading to earlier, more effective care.
DNAmito enables precise cancer treatment through its proprietary DNA technology and cloud platform. Our products leverage existing and open standards in the industry. DNAmito is vendor agnostic.
Prodecis DNAmito from Delbressine Media on Vimeo.
Who We Are
The DNAmito team is comprised of world class genomics and data scientists, accomplished entrepreneurs, software and product developers, clinical and industry experts, bringing years of experience and success to the company. They cultivate our strong innovative culture and work tirelessly to help our team to scale and succeed.
The DNAmito strategic advisory team has a wealth of experience in medical research, clinical oncology and regulatory. The members of the strategic advisory team come from leading academic institutions, medical practices as well as medical device companies.
DNAmito has a strategic partnership and licensing agreement with the Maastro Clinic and Maastricht University. Through this partnership, DNAmito has access to leading cancer research centers in Europe, Asia and the U.S.
Our Team
Partnerships
Clinical Data
Already funded NIH-registered trials include:
- Rapid Learning for Lung Cancer
- Biobank Carcinoma
- The Head and Neck Tumor Biobank
- Early-Stage Breast Cancer
Select collaborators and partners:
Prospective Multicenter Trials
Maastricht University is a partner in the Requite Consortium* (15 partners)
“Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors” (multicenter cohort study in Lung Breast and prostate cancer: 5,300 lung, breast and prostate cancer patients
Products
PRODECIS
Personalized Radiation Oncology Decision Support System™
AI based platform, clinical-grade predictive models that use multiple factors to compare various treatment options:
Extensibility beyond radiation oncology
oncologists | surgeons | tumor board
PRODECIS CLINICAL GRADE
Time, resources, expertise, and machine-learning in last 7 years to create Prodecis.
Years
Data Scientists
Peer Reviewed
Literature
Disease Sites
Models
Investigators
PRODECIS
"Optimizing outcome rather then dose"
Lambin et al. Nat Rev Clin Oncol 2013, Cheng Q, Roelofs E, Lambin P et al. Radiotherapy Oncol 2016
Multifactorial Decision Support System
Proprietary software & algorithms
Modeled and validated using data and tissue samples from partnership with 15 leading cancer centers and several already funded trials.
Lambin et al. Nat Rev Clin Oncol 2013, Cheng Q, Roelofs E, Lambin P et al. Radiotherapy Oncol 2016
Clinical Decision Support platform
Integrating Prodecis
CONTACT US
North America
DNAmito Inc.
2225 East Bayshore Road, Suite 200
Palo Alto, CA 94303 USA
650-687-0899
European Union
ptTheragnostic B.V.
Oxfordlaan 70
6229 EV Maastricht
The Netherlands